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Endoplasmic reticulum phosphate transport. The major role of the
liver endoplasmic reticulum phosphate/pyrophosphate transport proteins
is the regulation of blood glucose levels. The glucose-6-phosphatase
enzyme is an endoplasmic reticulum enzyme system which hydrolyzes
glucose-6-phosphate to glucose and phosphate. Glucose-6-phosphatase is
the terminal step of both gluconeogenesis and glycogenolysis. The glu-
cose-6-phosphatase enzyme is a very hydrophobic membrane protein and
its active site is inside the lumen of the endoplasmic reticulum. The
substrates and products of the enzyme therefore have to cross the
endoplasmic reticulum membrane. The glucose-6-phosphatase enzyme is
associated with a calcium binding protein (SP). There are also transport
proteins for the substrate glucose-6-phosphate (Ti) and the products
phosphate (T2) and glucose (T3). There appear to be at least two different
liver endoplasmic reticulum proteins that can transport phosphate. One of
the proteins T2b can also transport pyrophosphate and carbamyl phos-
phate which are also substrates for the glucose-6-phosphatase enzyme.
The metabolic regulation, genetic deficiencies, ontogeny and tissue distri-
bution of the endoplasmic reticulum T2 proteins will be described.
Most mammalian tissues cannot make sufficient amounts of
glucose to maintain their metabolic functions and need a contin-
uous supply from the bloodstream. Dietary supplies of glucose in
humans are intermittent and to maintain blood glucose levels
between meals, the body needs to be able to make glucose. The
liver is the major site of glucose production and it is very
important in the regulation of blood glucose levels [1]. In response
to a variety of stresses or low blood glucose levels the liver releases
glucose for use by other tissues. The two pathways by which the
liver can make glucose are glycogenolysis and gluconeogenesis [1,
2] (Fig. 1). One enzyme, microsomal glucose-6-phosphatase (EC
3.1.3.9) catalyzes the terminal step of both pathways [3, 4].
Glucose-6-phosphatase is an integral endoplasmic reticulum
membrane protein and its importance in regulation of blood
glucose levels was first demonstrated in 1952 [5] by the severe
metabolic disturbances in patients with genetic deficiencies of the
liver glucose-6-phosphatase enzyme.
In vitro, the glucose-6-phosphatase enzyme has been shown to
hydrolyze a number of substrates, such as pyrophosphate and
carbamyl phosphate and to catalyze a wide range of phospho-
transferase reactions [2], although the physiological significance of
many of these additional reactions has not been unequivocally
demonstrated. It has also been proposed that glucose-6-phos-
phatase may play a role in regulating hepatic cytosolic Ca2
concentrations [6—81.
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The glucose-6-phosphatase system
Early attempts to investigate glucose-6-phosphatase topology
were based on histochemical staining of the reaction product
phosphate and it was shown that the glucose-6-phosphatase
enzyme active site was inside the lumen of the liver endoplasmic
reticulum [9]. Glucose-6-phosphatase is unique among enzymes of
carbohydrate metabolism in that its active site is inside the lumen
of the endoplasmic reticulum whereas all the other enzymes
involved in gluconeogenesis and glycogen metabolism are else-
where in the cell (Fig. 1). This means that to allow glucose-6-
phosphatase to function normally its substrates and products must
be able to cross the endoplasmic reticulum membrane (Fig. 2).
The products of hydrolysis of glucose-6-phosphate are phosphate
and glucose both of which are inhibitors of glucose-6-phosphate
hydrolysis by the glucose-6-phosphatase enzyme.
The hepatic microsomal glucose-6-.phosphatase system has
been extensively characterized in the last few years [10] and for
normal glucose-6-phosphatase activity in vivo, several different
protein components are needed. The catalytic subunit of the
glucose-6-phosphatase enzyme is situated with its active site inside
the lumen of the endoplasmic reticulum and it is associated with
a regulatory Ca2 binding protein (Fig. 2). Three transport
systems termed Ti, T2 and T3 (GLUT 7) (Fig. 2) are also needed
to respectively transport the substrate glucose-6-phosphate [Ii]
and the products phosphate (and the substrate pyrophosphate)
and glucose across the liver endoplasmic reticulum membrane
[12—14]. The genetic evidence that endoplasmic facilitative trans-
port proteins for glucose-6-phosphate, phosphate/pyrophosphate
and glucose exist and the different symptoms of their human
genetic deficiencies (types ib, ic, and id glycogen storage disease,
respectively) has been repeatedly reviewed elsewhere [4, 15, 16].
Detailed discussion of the endoplasmic reticulum glucose-6-
phosphate and glucose transport proteins and the glucose-6-
phosphatase enzyme are outside the scope of this paper about
endoplasmic reticulum phosphate and pyrophosphate transport
[reviewed in 4, 10, 15].
Microsomal phosphate/pyrophosphate transport
The transport of phosphate produced in the lumen of the
endoplasmic reticulum has been termed T2 [17]. Anon and
coworkers [17] also proposed, based on kinetic evidence in rat
liver microsomes, that when pyrophosphate was the substrate of
the glucose-6-phosphatase enzyme it entered the endoplasmic
reticulum lumen via T2 and was hydrolyzed to two molecules of
phosphate both of which left the lumen via the same T2 transport
protein, Endoplasmic reticulum phosphate and pyrophosphate
transport is not nearly as well characterized as plasma membrane
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Fig. 1. Schematic representation of the pathways
of liver glucose production. Bold arrows indicate
pathways of glucose production.
Fig. 2. Schematic representation of the glucose-6-
phosphatase system with glucose-6 -phosphate as
substrate.
phosphate transport or mitochondrial phosphate transport. The
main reason is the difficulty in directly assaying phosphate effiux
from microsomes and/or endoplasmic reticulum. Plasma mem-
brane facilitative transport proteins are normally assayed by
measuring uptake or efflux of radioactively labeled substrates into
or out of the cells where the transport proteins occur naturally or
cells where they have been expressed, such as oocytes. Similar
types of experiments are very difficult to do with the endoplasmic
reticulum facilitative transport proteins as the microsomal intralu-
menal space is very small and the substrate can only equilibrate
with the lumenal water space. The intralumenal volume of liver
microsomes varies somewhat depending on the composition of
the buffer in which they are suspended, but the normal intralu-
menal volume measured is only about I pi/mg of microsomal
protein (such as [181). In addition the glucose-6-phosphatase
substrate and product transport systems all have very high Km's
CYTOPLASM
PPPi P1
2Pi
Fig. 3. Schematic representation of the proteins
of the glucose-6-phosphatase system which are
needed when pyrophosphate is the substrate.
(high mM) and very large transport capacities. This means that
direct measurement of labeled phosphate or pyrophosphate up-
take or efflux into or out of microsomes is difficult because the
transport is very rapid making it very difficult to measure initial
rates and relatively low numbers of counts are taken into or
released from the microsomal lumen. However, conventional
transport assays [19] in combination with kinetic analysis of the
glucose-6-phosphatase system using a variety of different sub-
strates alone or in combination with phosphate and glucose, which
are both inhibitors of the glucose-6-phosphatase enzyme [12, 20,
21], and assessment of microsomal uptake using light scattering
measurements [11, 22] clearly indicate that phosphate and pyro-
phosphate uptake occurs into and/or out of rat and human liver
microsomes,
T2 is the easiest of the glucose-6-phosphatase transport systems
to measure enzymatically because in intact microsomes the sub-
strate pyrophosphate is transported via T2 as is phosphate, the
only product of pyrophosphate hydrolysis (Fig. 3). Therefore, in
intact microsomes with pyrophosphate as substrate glucose-6-
phosphatase activity is a measure of the combined rates of T2 and
the enzyme. A rat liver endoplasmic reticulum phosphate/pyro-
phosphate transport protein has been purified and antibodies
have been raised against it [13, 23]. It was originally assumed that
there was only one endoplasmic reticulum phosphate transport
protein (called T2) and that the purified protein was T2. The
absence of the purified protein, as judged by immunoblot analysis
of microsomes, in some patients with type ic glycogen storage
disease seemed to confirm this [13, 231. However, an increasing
number of more recent studies [12, 20, 24] indicate that at least
two different endoplasmic reticulum phosphate transport proteins
must exist. The first evidence that there must be more than one
endoplasmic reticulum phosphate transport protein came from
studies of glycogen storage disease type ic.
Type ic glycogen storage disease
Types 1 a, b, c and d glycogen storage disease are a result of
impaired glucose-6-phosphatase activity. There is abnormal stor-
age of liver glycogen and fat. These defects impair glucose
production from both glycogen and gluconeogenesis. The clinical
manifestations are many and varied, including logical effects of
defective glucose production, such as growth retardation, hepato-
megaly, hypoglycemia, lactic acidemia and hyperlipidemia, and
others less easy to explain, such as neutropenia, recurrent infec-
tions, prolonged bleeding times. The severity of individual symp-
toms vary greatly between patients and rare virtually asymtomatic
cases occur. These diseases normally present in childhood but
surprisingly some present in adulthood. Long-term complications
include gout, hepatic adenomas, hepatomas and renal disease
[reviewed in 16, 25]. In the past, many patients with unrecognized
and/or untreated type 1 glycogen storage disease died in early
infancy from profound hypoglycaemia and acidosis. Other pa-
tients do not show all the classical symptoms and/or only have
relatively mild symptoms. Surprisingly even some patients with all
the classical symptoms are not diagnosed until adulthood. In rare
cases, type 1 glycogen storage disease patients may be asymptom-
atic. Histology of the liver is characterized by universal distension
of hepatocytes by glycogen and fat. Lipid vacuoles are particularly
large and prominent. There is no associated fibrosis [16]. In the
past 15 years, major progress has been made in managing this
disorder. Current treatment of type 1 glycogen storage disease is
nocturnal nasogastric infusion of glucose or orally administered
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Table 1. Glucose-6-phosphatase activity in human liver microsomes
Intact microsomes Disrupted microsomes
Vmax Km Vrnax Km
jimol/min/mg mM p.mol/minlmg mM
Glucose-6-phosphate
as substrate
control (N = 25) 0.15 0.02 2.6 0.23 0.30 0.03 0.7 0.07
Type ic GSD 0.14 0.02 7.3 1.13 0.23 0.03 0.8 0.08
(N = 7)
Pyrophosphate
as substrate
control (N = 25) 0.08 0.01 2.5 0.32 0.24 0.02 0.7 0.1
Type ic GSD 0 nd 0.15 0.02 0.5 0.1
(N = 7)
Abbreviation nd is not determinable.
uncooked cornstarch. Both are effective for sustaining the com-
monly measured metabolic indices of adequate therapy in type 1
glycogen storage disease. Early diagnosis and initiation of treat-
ment, has improved the prognosis with normal growth and
pubertal development and reduced risk of gout in adult patients.
It was initially suggested that with early treatment, adenomas,
hepato-cellular carcinomas and renal disease would not occur, but
there unfortunately is evidence that this is not always true, and
management by hepatic or renal transplantation or liver resection
may still be needed.
Type ic, first described in 1983 [40], has been reported in
relatively few patients compared to type la and lb glycogen
storage disease. In addition prior to recent improvements in
diagnosis of type 1 glycogen storage diseases, it is clear that some
type lc patients were mistakenly diagnosed as type lb glycogen
storage disease, so we do not yet have sufficient unequivocal
clinical information to allow for a general description of the
differences in the clinical manifestations from types la and lb and
ic glycogen storage disease.
Currently the only method of unequivocal diagnosis of type ic
glycogen storage disease is kinetic analysis of the glucose-6-
phosphatase system in intact and disrupted microsomes [16, 26].
In type ic glycogen storage disease the activity of the glucose-6-
phosphatase enzyme that is measured in disrupted microsomes is
normal (Table 1). In contrast, in intact microsomes with glucose-
6-phosphate as substrate the activity has an abnormally high Km
(Table 1); this results in abnormally low glucose-6-phosphatase
activity in vivo as the intracellular concentration of glucose-6-
phosphate in liver is low (<0.5 mM). As glucose-6-phosphatase
activity in intact microsomes is a measure of the combined rates of
the three transport protein systems and the enzyme, the high Km
indicates that one of the transport protein is defective. Analysis of
glucose-6-phosphatase activity with pyrophosphate as substrate in
type Ic glycogen storage disease shows normal activity in dis-
rupted microsomes but no activity in intact microsomes (Table 1),
demonstrating that pyrophosphate cannot be taken up into the
microsomal lumen. In type ic glycogen storage disease, the
abnormally high Km in intact microsomes with glucose-6-phos-
phate as substrate is caused by the presence of abnormally high
levels of phosphate in the microsomal lumen, which inhibit the
glucose-6-phosphatase enzyme. All the cases of glycogen storage
disease type Ic described so far in the literature including those in
Table 1 are defects in the pyrophosphate/phosphate transport
protein T2b. If T2b was the only microsomal phosphate transport
protein, then it would be expected that when glucose-6-phosphate
is the substrate in intact microsomes, phosphate would be trapped
and accumulate in the lumen, and this would cause glucose-6-
phosphatase activity to decrease due to phosphate inhibition. This
does not occur, glucose-6-phosphatase activity although signifi-
cantly lower than normal remains linear with time in intact
microsomes. The simplest explanation for this is that a second
high Km phosphate transport mechanism exists in the endoplas-
mic reticulum, which allows phosphate to be released when it
reaches high concentrations inside the lumen.
Regulation of microsomal phosphate/pyrophosphate transport
Very little is known about the regulation of liver endoplasmic
reticulum phosphate transport, but some recent studies have shown
that it is regulated in a variety of metabolic states. Studies of
pyrophosphate activity and phosphate inhibition of glucose-6-phos-
phatase activity in mice have shown that the levels of expression of
T2b in liver microsomes change in animals with Erlich-ascites tumors
[20, 24], and that different forms of T2 exist with different Km's and
transport capacities. In very recent preliminary studies we have also
shown that liver microsomal phosphate uptake changes in fed,
starved and diabetic animals (Benedetti and Burchell, unpublished
results) with the highest uptake in fed and the lowest in diabetic liver
microsomes. This was an unexpected finding as the activity of the
liver glucose-6-phosphatase enzyme changes in the opposite direc-
tion bethg highest in diabetes and lowest in the fed state.
The ontogeny of human microsomal liver and kidney
phosphate/pyrophosphate transport
At term the expression of all the proteins of the liver glucose-
6-phosphatase system increases dramatically (10- to 20-fold) in
the first three days after birth [27]. In human embryonic liver, the
glucose-6-phosphatase enzyme can be immunohistochemically
detected as early as 32 post-ovulatory days [28]. In human fetal
liver glucose-6-phosphatase enzyme activity can first be measured
enzymatically from about 10 to 11 weeks gestation, but T2b
protein and transport capacity seems to be delayed in comparison
becoming measurable 2 to 3 weeks later [27]. In contrast, in
human fetal kidney there is a common spatial and temporal
expression of both the T2b protein and the catalytic unit of the
glucose-6-phosphatase system [29]. Consistent with this is the low
latency of glucose-6-phosphatase activity in intact human fetal
kidney microsomes with pyrophosphate as substrate, which shows
that the level of T2 transport capacity is appropriate for the
amount of enzyme activity present. This is in complete contrast to
the high latency (up to 100%) of glucose-6-phosphatase activity in
intact human fetal liver microsomes with pyrophosphate as sub-
strate that we found in liver samples of the same gestational range
[12, 27]. The earlier temporal expression of the endoplasmic
reticulum pyrophosphate (and carbamyl phosphate) transport
capacity in kidney compared to liver may reflect the importance of
pyrophosphate and carbamyl phosphate as substrates in human
fetal kidney.
Tissue distribution of endoplasmic reticulum
phosphate/pyrophosphate transport protein(s)
Classically the glucose-6-phosphatase system was thought to
only be present in significant quantities in the gluconeogenic
organs (liver and kidney) with lower levels being present in gut.
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Table 2. Human tissues in which microsomal glucose-6-phosphatase
has been found
Tissue
Predominant
distribution
Developmental
stage
Liver [5, 32—34] hepatocytes fetal
adult
Kidney [28, 29] proximal tubules
collecting ducts
loop of Hcnle
distal tubules
embryonic
fetal
adult
Adrenal [22, 28] fetal zone fetal
Brain [28]
Intestine [28, 35]
some but not all
astrocytes
mucosa
fetal
adult
adult
Trachea [28, 39] epithelium fetal
Oesophagus [28, 391 epithelium fetal
Gallbladder [38] mucosa adult
Red blood cells [36, 37] nucleated red
blood cells
embryonic
fetal
The fact that some patients with type ic glycogen storage disease
also develop diabetes [30, 40] prompted us to look for glucose-6-
phosphatase in pancreas and we found high levels of glucose-6-
phosphatase activity in pancreatic islets [31]. More recently we
have also shown the expression of glucose-6-phosphatase protein
and mRNA in pancreas. We then decided to determine if
glucose-6-phosphatase was also present in minor cell types in a
variety of tissues throughout human development and Table 2
summarizes our findings to date. In all cases where we have found
glucose-6-phosphatase we have also found the other components
of the system including phosphate transport. For example, we
have shown in human adrenal, using monospecific antisera and
immunohistochemical methods, that the glucose-6-phosphatase
system (glucose-6-phosphatase catalytic unit, T2 and T3) is
present during embryonic and fetal development, and that it is
predominantly localized to the metabolically active fetal zone,
with much lesser amounts in the definitive zone. We have also
demonstrated that the adrenal glucose-6-phosphatase enzyme is
as active in human fetal adrenal microsomes as it is in liver of the
same gestational age. In addition we have shown uptake of
glucose-6-phosphate, phosphate and glucose into fetal adrenal
microsomes [22]. The role of glucose-6-phosphatase in all these
tissues is not clear, in islets it may well play a role in the regulation
of glucose stimulated insulin release, and in some other tissues,
such as brain it may have a role in local glucose production.
Future
To fully understand the molecular basis of glycogen storage
disease type Ic and the role of each of the endoplasmic reticulum
transport proteins the transport proteins need to cloned and
expressed. However, it is clear from recent studies using a variety
of different types of assay methods that the endoplasmic reticulum
transport proteins play an important role in the glucose-6-phos-
phatase system, and that their regulation in a variety of metabolic
states results in the modification of glucose-6-phosphatase activity
in intact microsomes.
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